181 related articles for article (PubMed ID: 32222367)
1. A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.
Ta CN; Raizman MB; Gross RD; Joshi S; Mallick S; Wang Y; Segal B
Am J Ophthalmol; 2020 Jul; 215():56-65. PubMed ID: 32222367
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
Pepose JS; Ahuja A; Liu W; Narvekar A; Haque R
Am J Ophthalmol; 2018 Oct; 194():7-15. PubMed ID: 29787732
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children.
Isenberg SJ; Apt L; Valenton M; Del Signore M; Cubillan L; Labrador MA; Chan P; Berman NG
Am J Ophthalmol; 2002 Nov; 134(5):681-8. PubMed ID: 12429243
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
5. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
6. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis.
Pelletier JS; Stewart K; Trattler W; Ritterband DC; Braverman S; Samson CM; Liang B; Capriotti JA
Adv Ther; 2009 Aug; 26(8):776-83. PubMed ID: 19756415
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis.
Pepose JS; Narvekar A; Liu W; Haque R
Clin Ophthalmol; 2019; 13():535-544. PubMed ID: 30962674
[TBL] [Abstract][Full Text] [Related]
8. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
Sanfilippo CM; Allaire CM; DeCory HH
Drugs R D; 2017 Mar; 17(1):167-175. PubMed ID: 28078599
[TBL] [Abstract][Full Text] [Related]
9. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
DeLeon J; Silverstein BE; Allaire C; Gearinger LS; Bateman KM; Morris TW; Comstock TL
Clin Drug Investig; 2012 May; 32(5):303-17. PubMed ID: 22420526
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
Comstock TL; Paterno MR; Decory HH; Usner DW
Clin Drug Investig; 2010; 30(10):675-85. PubMed ID: 20629472
[TBL] [Abstract][Full Text] [Related]
13. Recurrent conjunctivitis secondary to Gram-positive bacillus, Bacillus thuringiensis.
Borgman CJ
Clin Exp Optom; 2018 Jul; 101(4):594-595. PubMed ID: 28626992
[No Abstract] [Full Text] [Related]
14. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
[TBL] [Abstract][Full Text] [Related]
15. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.
Tepedino ME; Heller WH; Usner DW; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL
Curr Med Res Opin; 2009 May; 25(5):1159-69. PubMed ID: 19323612
[TBL] [Abstract][Full Text] [Related]
16. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study.
Kovalyuk N; Kaiserman I; Mimouni M; Cohen O; Levartovsky S; Sherbany H; Mandelboim M
Acta Ophthalmol; 2017 Dec; 95(8):e686-e692. PubMed ID: 28342227
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis.
Belfort R; Gabriel L; Martins Bispo PJ; Muccioli C; Zacharias Serapicos PC; Clark L; Bell B; Bartell J; Stroman DW; Höfling-Lima AL
Adv Ther; 2012 May; 29(5):416-26. PubMed ID: 22562783
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of topical povidone-iodine during the first week after ophthalmic surgery.
Isenberg SJ; Apt L; Yoshimori R; Pham C; Lam NK
Am J Ophthalmol; 1997 Jul; 124(1):31-5. PubMed ID: 9222229
[TBL] [Abstract][Full Text] [Related]
19. Success of Masking 5% Povidone-Iodine Treatment: The Reducing Adenoviral Patient Infected Days Study.
Whiteside MM; Shorter ES; Margolis MS; Alvi F; Huecker JB; Than TP; Migneco MK; Harthan JS; Morettin CE; Hartwick ATE; Johnson SD; Perera CD; Gordon MO
Optom Vis Sci; 2021 May; 98(5):469-475. PubMed ID: 33973917
[TBL] [Abstract][Full Text] [Related]
20. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
